GENESIS to distribute Santhera’s Agamree in Central and Eastern Europe

Swiss specialty pharma firm Santhera Pharmaceuticals (SIX: SANN) has signed an exclusive distribution agreement with GENESIS Pharma for Agamree (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in 20 markets in Central and Eastern Europe.

This strategic collaboration aims to address unmet medical needs by allowing GENESIS Pharma to commercialize Agamree in Greece, Cyprus, Malta, Romania, Bulgaria, Slovenia, Croatia, Poland, Czech Republic, Hungary, Slovakia, Lithuania, Latvia, Estonia, Serbia, North Macedonia, Bosnia & Herzegovina, Montenegro, Albania, and Kosovo.

“This distribution agreement with GENESIS Pharma marks a significant achievement for Santhera as we expand the global availability of Agamree. By partnering with expert organizations with a strong understanding of specialist markets, we ensure optimal patient access,” said Dr Geert Jan van Daal, chief commercial officer of Santhera, adding: “This is a further step in our strategy to allow focus on key European markets with dedicated Santhera teams while partnering with the best companies for non-core European markets.”